Long Term Follow-up Results of Brl-201 Phase I Study, a Crispr-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma

被引：1
|
作者：
Zheng, Biao [1 ]
Hu, Yongxian [2 ,3 ,4 ,5 ]
Zhang, Jiqin [1 ]
Zhang, Mingming [2 ,3 ,4 ,5 ]
Li, Wei [1 ]
Wu, Wenjun [2 ,3 ,4 ,5 ]
Cui, Jiazhen [2 ,3 ,4 ,5 ]
Wei, Guoqing [2 ,3 ,4 ,5 ]
Du, Bing [1 ,6 ,7 ]
Liu, Mingyao [1 ,6 ,7 ]
Huang, He [2 ,3 ,4 ,5 ]
机构：
[1] BRL Med Inc, Shanghai, Peoples R China
[2] Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China
[3] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China
[4] Zhejiang Univ, Liangzhu Lab, Med Ctr, Hangzhou, Peoples R China
[5] Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Peoples R China
[6] East China Normal Univ, Shanghai Frontiers Sci Ctr Genome Editing & Cell, Inst Biomed Sci & Sch Life Sci, Shanghai Key Lab Regulatory Biol, Shanghai, Peoples R China
[7] East China Normal Univ, Sch Life Sci, Shanghai, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185573
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 29 条
  • [21] Production of KTE-C19 (Anti-CD19 CAR T Cells) for ZUMA-1: A Phase 1/2 Multi-Center Study Evaluating Safety and Efficacy in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
    Better, Marc
    Chiruvolu, Vijay
    Oliver, James
    Lowe, Emily
    Rossi, John M.
    Perez, Arianne
    Navale, Lynn
    Bot, Adrian
    MOLECULAR THERAPY, 2016, 24 : S115 - S115
  • [22] Updated Phase 1 Results from ZUMA-1: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 (Anti-CD19 CAR T Cells) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
    Locke, Frederick L.
    Neelapu, Sattva S.
    Bartlett, Nancy L.
    Siddiqi, Tanya
    Chavez, Julio C.
    Hosing, Chitra M.
    Ghobadi, Armin
    Budde, Lihua E.
    Bot, Adrian
    Rossi, John M.
    Sherman, Marika
    Navale, Lynn
    Elias, Meg
    Wiezorek, Jeff
    Go, William Y.
    MOLECULAR THERAPY, 2016, 24 : S294 - S294
  • [23] UPDATED RESULTS FROM ZUMA-1: A PHASE 1-2 MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF KTE-C19 (ANTI-CD19 CAR T CELLS) IN REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (NHL)
    Siddiqi, T.
    Neelapu, S. S.
    Locke, F. L.
    Bartlett, N. L.
    Chavez, J. C.
    Hosing, C.
    Cashen, A. F.
    Budde, L. E.
    Rossi, J.
    Sherman, M.
    Navale, L.
    Jiang, Y.
    Aycock, J.
    Elias, M.
    Wiezorek, J. S.
    Go, W. Y.
    HAEMATOLOGICA, 2016, 101 : 318 - 318
  • [24] HR001, a novel CD19-targeted CAR-T cell therapy for patients with relapsed/refractory non-Hodgkin's lymphoma: primary results of a phase II study (HRAIN01-NHL01-II)
    Zhang, Yian
    Li, Yuhua
    Hu, Kai
    Li, Wuping
    Xue, Hongwei
    Deng, Qi
    Ge, Zheng
    Geng, Liangquan
    Song, Xianmin
    Yu, Kang
    Jing, Hongmei
    Chen, Bing
    Li, Xin
    Zhai, Zhimin
    Shen, Jianping
    Cao, Jiang
    Wang, Qingming
    Liu, Peng
    CANCER RESEARCH, 2024, 84 (07)
  • [25] Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
    Locke, Frederick L.
    Neelapu, Sattva S.
    Bartlett, Nancy L.
    Siddiqi, Tanya
    Chavez, Julio C.
    Hosing, Chitra M.
    Ghobadi, Armin
    Budde, Lihua E.
    Navale, Lynn
    Aycock, Jeff S.
    Wiezorek, Jeff
    Go, William Y.
    BLOOD, 2015, 126 (23)
  • [26] Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
    Rossi, John M.
    Neelapu, Sattva S.
    Go, William Y.
    Shen, Yueh-wei
    Sherman, Marika
    Locke, Frederick L.
    Bartlett, Nancy L.
    Siddiqi, Tanya
    Navale, Lynn
    Elias, Meg
    Wiezorek, Jeff
    Bot, Adrian
    BLOOD, 2015, 126 (23)
  • [27] Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL).
    Neelapu, Sattva Swarup
    Locke, Frederick Lundry
    Bartlett, Nancy L.
    Siddigi, Tanya
    Chavez, Julio C.
    Hosing, Chitra
    Cashen, Amanda F.
    Budde, L. Elizabeth
    Bot, Adrian
    Rossi, John
    Navale, Lynn
    Jiang, Yizhou
    Aycock, Jeff
    Elias, Meg
    Wiezorek, Jeffrey S.
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Ongoing complete remissions in phase 1 of ZUMA-1: a phase 1-2 multi-center study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in patients with refractory aggressive B cell non-Hodgkin lymphoma (NHL)
    Locke, F. L.
    Neelapu, S. S.
    Bartlett, N. L.
    Siddiqi, T.
    Chavez, J. C.
    Hosing, C. M.
    Cashen, A.
    Budde, L. E.
    Sherman, M.
    Rossi, J. M.
    Navale, L.
    Jiang, Y.
    Aycock, J.
    Elias, M.
    Wiezorek, J.
    Go, W. Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up
    Li, Ping
    Yu, Wen-Juan
    Zhou, Lili
    Yang, Min
    Ye, Shiguang
    Zhu, Judy
    Huang, Jiaqi
    Zhang, Yan
    Li, Lanfang
    Zhao, Jing
    Zhu, Kevin
    Li, Jing
    Zheng, Chengxiao
    Lan, Liping
    Wan, Hui
    Yao, Yihong
    Zhang, Huilai
    Zhou, Daobin
    Jin, Jie
    Liang, Aibin
    BLOOD, 2023, 142
123